Literature DB >> 12113294

Serum adenosine deaminase and cytidine deaminase activities in patients with systemic lupus erythematosus.

Seyithan Taysi1, M Fevzi Polat, Refik Ali Sari, Ebubekir Bakan.   

Abstract

We evaluated serum total adenosine deaminase, its isoenzymes adenosine deaminase-1 and adenosine deaminase-2, and cytidine deaminase activities in 24 patients with active systemic lupus erythematosus, and in 26 healthy control subjects, and found the means +/- SD values to be 21.38 +/- 5.96 IU/l, 3.74 +/- 2.12 IU/l, 17.72 +/- 5.02 IU/l and 17.89 +/- 4.62 IU/l, respectively in the patients, and 14.97+/- 4.71 IU/l, 4.01 +/- 1.35 IU/l, 10.91 +/- 3.91 IU/l and 7.39 +/- 3.97 IU/l, respectively in the control subjects. When compared to the healthy controls, serum total adenosine deaminase, adenosine deaminase-2 and cytidine deaminase levels were significantly higher (p<0.001) in systemic lupus erythematosus patients, but the decrease of adenosine deaminase-1 level was not statistically significant (p>0.05). The increased adenosine deaminase-2 may be of macrophage origin. It closely correlated with clinical signs of active systemic lupus erythematosus. The membranes of polymorphonuclear neutrophils may be damaged, and cytidine deaminase may be released into serum. In conclusion, serum total adenosine deaminase, adenosine deaminase-2 and cytidine deaminase activities may serve as useful indicators for evaluating disease activity in patients with active systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113294     DOI: 10.1515/CCLM.2002.085

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  4 in total

Review 1.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

3.  Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity.

Authors:  Zhao-Wei Gao; Guan-Hua Zhao; Zhe Zhang; Jing Huang; Zi-Yue Li; Hui-Zhong Zhang; Ke Dong
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

4.  Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants.

Authors:  Chao Xuan; Qing-Wu Tian; Shao-Yan Zhang; Hui Li; Ting-Ting Tian; Peng Zhao; Kang Yue; Yan-Yan Ling; Guo-Wei He; Li-Min Lun
Journal:  Ther Adv Chronic Dis       Date:  2019-12-06       Impact factor: 5.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.